Amphastar Pharmaceuticals
AMPH
203 hedge funds and large institutions have $1.07B invested in Amphastar Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 69 increasing their positions, 61 reducing their positions, and 19 closing their positions.
189% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 19
58% more capital invested
Capital invested by funds: $678M → $1.07B (+$392M)
21% more funds holding
Funds holding: 168 → 203 (+35)
13% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 61
1.01% more ownership
Funds ownership: 60.96% → 61.98% (+1%)
93% less call options, than puts
Call options by funds: $2.66M | Put options by funds: $37.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$7.14M |
| 2 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$6.65M |
| 3 |
PCM
Penserra Capital Management
Orinda,
California
|
+$5.07M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$4.96M |
| 5 |
FA
Friess Associates
Greenville,
Delaware
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$17.3M |
| 2 |
Goldman Sachs
New York
|
-$13.4M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$4.82M |
| 4 |
SAM
Silvercrest Asset Management
New York
|
-$3.61M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.33M |
AMPH Hedge Fund Activity: Q1 2022 in Review
203 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2022, worth a combined $1.07B — up 58% from $678M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new AMPH positions and 19 closed out — a net gain of 36 holders — while 69 added to existing stakes and 61 trimmed.
The largest buyer was Mesirow Financial Investment Management - Fixed Income, opening a new position worth an estimated $7.14M. The largest seller was Janus Henderson Group, cutting an estimated $17.3M.
- 203 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2022, up from 168 in Q4 2021.
- Funds reported $1.07B of Amphastar Pharmaceuticals stock for Q1 2022, up 58% quarter-over-quarter.
- 55 funds opened new Amphastar Pharmaceuticals positions in Q1 2022 and 19 closed out, a net change of +36 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2022 was Mesirow Financial Investment Management - Fixed Income, an estimated $7.14M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2022 was Janus Henderson Group, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2022.